Questions and Answers
What classification does Umeclidinium / Vilanterol fall under?
What are the trade names for Umeclidinium / Vilanterol?
Anoro, Ellipta
What route is used to administer Umeclidinium / Vilanterol?
DPI
What is the dosage and frequency for Umeclidinium / Vilanterol?
Signup and view all the answers
What is the primary action of Umeclidinium / Vilanterol?
Signup and view all the answers
What is Umeclidinium / Vilanterol used for?
Signup and view all the answers
What is the duration of action for Umeclidinium / Vilanterol?
Signup and view all the answers
What is the onset of action for Umeclidinium / Vilanterol?
Signup and view all the answers
Some side effects of Umeclidinium / Vilanterol include sore throat, muscle spasms, sinusitis, and __________.
Signup and view all the answers
Study Notes
Umeclidinium / Vilanterol Overview
- This drug is a combination medication classified as a bronchodilator.
- Common trade names include Anoro and Ellipta.
Administration and Dosage
- Delivered via a dry powder inhaler (DPI).
- Prescribed dosage is 62.5 mcg of Umeclidinium and 25 mcg of Vilanterol, administered as one inhalation daily.
Mechanism of Action
- The primary action is bronchodilation, which helps to open airways in the lungs.
Indications for Use
- Specifically used for treating COPD-related bronchospasms, improving airflow and breathing.
Pharmacokinetics
- The duration of action is approximately 24 hours, allowing for once-daily dosing.
- Onset of action occurs within 5 to 15 minutes after administration, providing quick relief.
Potential Side Effects
- Common side effects include sore throat, muscle spasms, sinusitis, and respiratory tract infections.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Explore the essential information about Umeclidinium and Vilanterol, a combined bronchodilator used in COPD management. This quiz covers administration, dosage, mechanism of action, and potential side effects. Test your knowledge on this medication's therapeutic use and pharmacokinetics.
